TD Cowen analyst Tara Bancroft has maintained their bullish stance on IRON stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tara Bancroft’s rating is based on several compelling factors that highlight Disc Medicine’s potential for growth and innovation. One of the key reasons is the promising outlook for bitopertin, a first-in-class treatment for erythropoietic protoporphyria (EPP), a rare disorder with no current disease-modifying therapies. The Phase II data showed significant improvements, including a notable reduction in PPIX levels and increased tolerance to light, which positions bitopertin as a potential game-changer in its field. The recent submission of the NDA and the FDA’s positive response further bolster confidence in its accelerated approval and future success.
Additionally, the potential market for bitopertin is substantial, with an estimated $700 million opportunity if it captures just a fraction of the target patient population. Beyond bitopertin, Disc Medicine’s pipeline includes DISC-0974, which has shown impressive results in treating anemia of myelofibrosis (MF). The Phase Ib results exceeded standard therapy benchmarks, and the ongoing Phase II trial could unlock a significant market opportunity if successful. These factors collectively underscore the strong potential for Disc Medicine’s stock, justifying the Buy rating.
In another report released on November 14, H.C. Wainwright also maintained a Buy rating on the stock with a $118.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year.